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Abstract
Aims/hypothesis We studied the association of plasma ascorbic acid with the risk of developing islet autoimmunity and type 1
diabetes and examined whether SNPs in vitamin C transport genes modify these associations. Furthermore, we aimed to
determine whether the SNPs themselves are associated with the risk of islet autoimmunity or type 1 diabetes.
Methods We used a risk set sampled nested case–control design within an ongoing international multicentre observational study:
The Environmental Determinants of Diabetes in the Young (TEDDY). The TEDDY study followed children with increased
genetic risk from birth to endpoints of islet autoantibodies (350 cases, 974 controls) and type 1 diabetes (102 cases, 282 controls)
in six clinical centres. Control participants were matched for family history of type 1 diabetes, clinical centre and sex. Plasma
ascorbic acid concentration was measured at ages 6 and 12 months and then annually up to age 6 years. SNPs in vitamin C
transport genes were genotyped using the ImmunoChip custom microarray. Comparisons were adjusted for HLA genotypes and
for background population stratification.
Results Childhood plasma ascorbic acid (mean ± SD 10.76 ± 3.54 mg/l in controls) was inversely associated with islet autoimmunity
risk (adjusted OR 0.96 [95%CI 0.92, 0.99] per +1mg/l), particularly islet autoimmunity, starting with insulin autoantibodies (OR 0.94
[95% CI 0.88, 0.99]), but not with type 1 diabetes risk (OR 0.93 [95% Cl 0.86, 1.02]). The SLC2A2 rs5400 SNP was associated with
increased risk of type 1 diabetes (OR 1.77 [95% CI 1.12, 2.80]), independent of plasma ascorbic acid (OR 0.92 [95% CI 0.84, 1.00]).
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Conclusions/interpretation Higher plasma ascorbic acid levels may protect against islet autoimmunity in children genetically at
risk for type 1 diabetes. Further studies are warranted to confirm these findings.
Data availability The datasets generated and analysed during the current study will be made available in the NIDDK Central
Repository at https://www.niddkrepository.org/studies/teddy.
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Abbreviations
DHA Dehydroascorbic acid
GADA GAD autoantibody
IAA Insulin autoantibody
IA-2A Autoantibody to tyrosine phosphatase-related islet
antigen 2
NIST National Institute of Standards and Technology
SLC2A Solute carrier family 2
SVCT Sodium L-ascorbic acid transporter
TEDDY The Environmental Determinants of Diabetes in
the Young
Introduction
Oxidative stress may play a role in the pathogenesis of type 1
diabetes for several reasons. The cells in pancreatic islets are
more vulnerable to oxidative damage than many other cells
due to the low activity of free-radical detoxifying and redox-
regulating enzymes such as catalase, superoxide dismutase
and glutathione peroxidase [1]. It has been hypothesised that
dietary antioxidants might improve the islets’ capacity to cope
with oxidative stress (e.g. induced by hyperglycaemia) [1–4].
Vitamin C (ascorbic acid) is a water-soluble vitamin obtain-
ed from vegetables, fruits and berries [5]. As a dietary
antioxidant vitamin C might protect against the development
of type 1 diabetes [6]. However, only two case–control studies
have investigated the issue. In an Australian study, use of vita-
min C supplements was less frequent in children with type 1
diabetes before onset [7]. On the other hand, a Swedish study
found no differences in dietary vitamin C intake before onset
between type 1 diabetes cases and controls [8]. The association
between plasma ascorbic acid concentration and islet autoim-
munity or the subsequent development of type 1 diabetes has
not been investigated. Plasma ascorbic acid represents the most
accurate measure of available vitamin C in the body [9, 10].
Genetic variation in vitamin C metabolic pathways causes
inter-individual differences in plasma and tissue ascorbic acid
availability [9], which might similarly contribute to type 1
diabetes risk. The metabolism of ascorbic acid is regulated
by key proteins called sodium L-ascorbic acid transporters
(SVCTs). Two isoforms, hSVCT1 and hSVCT2, encoded by
the genes SLC23A1 and SLC23A2, respectively, control the
active transport of ascorbic acid across cell membranes and
uptake to tissues [11]. hSVCT1 expression is confined to
epithelia in renal, intestinal and hepatic tissues, while
hSVCT2 is responsible for tissue-specific uptake.
The SNP rs33972313, a low-frequency missense variant in
SLC23A1, has been consistently associated with lower circu-
lating ascorbic acid status [11]. Other SNPs in SLC23A1
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(intronic SNPs rs6596473 and rs4257763, and promoter SNP
rs10063949) have also been associated with ascorbic acid
concentration, but less consistently. Furthermore, intronic
SNPs (rs6053005 and rs1279683) in SLC23A2 have been
associated with ascorbic acid concentration [11–14]. Less is
known about the importance of the second pathway, the solute
carrier family 2 (SLC2A; also called GLUT) family proteins
that transport dehydroascorbic acid (DHA) into cells where it
is converted into ascorbic acid [15].
The aim of this study was to examine the association of
plasma ascorbic acid concentration with the risk of islet auto-
immunity and type 1 diabetes in children with a high genetic
risk of type 1 diabetes. Furthermore, we studied the associa-
tion of plasma ascorbic acid with the risk of islet autoimmu-
nity relative to the first autoantibody to be observed (either
insulin autoantibody [IAA] or GAD autoantibody [GADA],
referred to hereafter as IAA first and GADA first, respective-
ly), because the type of autoantibody appearing first may
reflect different disease processes [16–18]. In addition, we
examined whether vitamin C metabolism genes available on
the ImmunoChip are associated with, or modify, the associa-
tion between plasma ascorbic acid and the development of
islet autoimmunity and type 1 diabetes. This included a
protein-coding missense SNP in SLC23A1 (rs33972313),
two intronic SLC2A1 (also known as GLUT1, 1p34.2) SNPs
(rs1105297 and rs3754223), and an SLC2A2 (also known as
GLUT2, 3q26.2) SNP (rs5400) in the dehydro-L-ascorbic acid
transport genes.
Methods
Study design The study was performed as a nested case–
control study within The Environmental Determinants of
the Diabetes in the Young (TEDDY) study. The TEDDY
study is an international multicentre observational cohort
study that prospectively follows children from birth in the
search for environmental factors involved in the develop-
ment of islet autoimmunity and subsequent type 1 diabetes
in genetically susceptible children (based upon HLA geno-
type), as described in detail previously [19, 20]. Written
informed consents have been obtained for all study partic-
ipants, from a parent or primary caretaker, separately, for
genetic screening and participation in prospective follow-
up visits. The study is funded by the National Institutes of
Health (NIH) and the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK) and approved
by local Institutional Review Boards and monitored by an
External Advisory Board. The TEDDY study is conducted
in clinical research centres in the USA (Colorado, Georgia/
Florida, Washington State), Finland, Sweden and
Germany.
Study population Between 1 September 2004 and 28
February 2010, a total of 424,788 new-born infants were
screened for type 1 diabetes-associated HLA genotypes.
Eligibility criteria for initial contact was one of the following
HLA class II genotypes: HLA-DR3/4; HLA-DR4/4; HLA-
DR4/8; HLA-DR3/3 and HLA-DR4/4. Infants with HLA-DR
genotypes HLA-DR4/1, HLA-DR4/13, HLA-DR4/9 and HLA-
DR3/9 were included only if they had a first-degree relative
(i.e. mother, father or sibling) with type 1 diabetes [21]. Of the
eligible infants, 21,589 had type 1 diabetes genetic risk based
on HLA genotyping and 8676 children were enrolled.
Children were followed every 3 months with a scheduled
clinic visit until the age of 4 years, and every 6 months there-
after until being diagnosed with type 1 diabetes. Children with
islet autoimmunity were followed every 3 months throughout
the study. Of the enrolled children, 2211 (25.5% of the 8676)
were withdrawn or lost to follow-up by 6 years of age at the
time of the design.
Outcomes The primary outcomes in this study were persistent
confirmed islet autoimmunity and the diagnosis of type 1
diabetes. Persistent confirmed islet autoimmunity was defined
by appearance of one or more islet cell autoantibodies (IAA,
GAD, or autoantibody to tyrosine phosphatase-related islet
antigen 2 [IA-2A], also known as insulinoma antigen-2 anti-
body) confirmed at two consecutive visits. Type 1 diabetes
diagnosis was based on American Diabetes Association
criteria [22]. Different autoantibodies may be associated with
different disease processes [16–18] and therefore secondary
analyses were conducted regarding timing of autoantibodies:
IAA first and GADA first.
Nested case–control design
The current study was performed with risk set sampling
described previously [23]. The study was conducted in two
nested case–control designs within the TEDDY study: (1) for
islet autoimmunity outcome; and (2) for type 1 diabetes
outcome. Three matched controls were selected per islet auto-
immunity and type 1 diabetes case. Children were matched for
family history of type 1 diabetes, clinical centre and sex. The
nested case–control study sets were based on the data collect-
ed as of 31 May 2012 [23].
The islet autoimmunity outcome analysis included 350
cases with median seroconversion age of 23 months (range
6–72 months) and 974 matched controls. Islet autoimmunity
cases were defined as a participant with persistent islet auto-
immunity. A control was defined as a participant who had not
developed persistent islet autoimmunity by the time that the
corresponding matched case had done, plus 45 days. The islet
autoimmunity case–control set used for the statistical analyses
consisted of 3371 plasma samples taken for ascorbic acid
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measurement. Three hundred and sixty-five samples failed the
laboratory’s internal quality control. Samples from controls
were processed only when the matched case had an available
sample at a corresponding visit. The mean ascorbic acid level
for each child was calculated from all available measurements.
Type 1 diabetes outcome analysis consisted of 102 caseswith
median age of 31 months at diagnosis (range 8–75 months) and
282 matched controls. A control for a type 1 diabetes case was
defined as a participant who had not developed type 1 diabetes
by the time the corresponding matched case had done so, plus
45 days. Of the 350 islet autoimmunity cases, 74 were also
analysed as type 1 diabetes cases. Those islet autoimmunity
cases who developed type 1 diabetes but had seroconverted
already before the first plasma sample was collected for ascorbic
acid measurement (collection started at 6 months of age) were
included only in the type 1 diabetes analysis. Thus, 28 type 1
diabetes cases were included only for type 1 diabetes analysis.
Secondary outcome analyses were performed within the
islet autoimmunity nested case–control design. The islet auto-
immunity dataset included 163 IAA first cases with median
seroconversion age of 18 months (range 6–72 months) and
450 controls. Within the islet autoimmunity dataset there were
120 GADA first cases with median seroconversion age of
28 months (range 6–68 months) with 336 controls.
Plasma ascorbic acid measurements Plasma samples for
ascorbic acid measurement were collected at the age of
6 months and 12 months, and then annually until 6 years of
age or until and including the time of seroconversion of the
islet autoimmunity cases, and for type 1 diabetes cases the
visit just preceding the type 1 diabetes diagnosis (with corre-
sponding time for matched controls). Stabilisers were added to
plasma samples intended for ascorbic acid analysis before
freezing to minimise degradation of ascorbic acid [24]. After
sample collection at the clinical centres, 50 μl of sodium
citrate plasma (in BD Vacutainer CPT Cell Preparation
Tubes [Becton Dickinson, Franklin Lakes, NJ, USA]) was
transferred into cryovials and 0.2 ml of 5% (wt/vol.) trichlo-
roacetic acid and 200 mg disodium EDTA was added, with
subsequent freezing at −70°C. A long-distance protocol was
developed for the collection of blood samples from families
living away from their nearest TEDDY study clinic (most
frequently being the case in Germany compared with the other
countries). In the long-distance collection protocol, blood
samples were obtained by a family paediatrician and
transported within 24 h to the TEDDY study clinic site.
Case samples were paired with matched control samples and
randomly placed within a batch before samples were
transported to the laboratory.
Ascorbic acid measurements were performed at the
Biochemistry Laboratory, Genomics and Biomarkers Unit,
National Institute for Health and Welfare (THL), Helsinki,
Finland. Ascorbic acid was determined by an ion-paired,
reversed-phase, high-performance liquid chromatographic
method using electrochemical detection, as described [24].
Isoascorbic acid was used as internal standard for the quantifi-
cation of ascorbic acid. The laboratory staff were blinded to the
case–control status of samples. The laboratory included three
internal quality control samples of three ascorbic acid levels in
each run (altogether nine samples). Precision within the project,
expressed as the CV of the quality control samples, was 9.2–
12.6% at a concentration range of 4.6–11.2 mg/l. During the
project, the laboratory participated three times in an external
quality assessment scheme (National Institute of Standards and
Technology (NIST) Micronutrients Measurement Quality
Assurance Program for Total Ascorbic Acid). The results were
in excellent concordance with NIST values.
Genotyping Illumina Infinium ImmunoChip custom microar-
ray was used for SNP genotyping, based upon robust genome-
wide association analyses (GWAS) in 12 autoimmune
diseases (including type 1 diabetes). The ImmunoChip array
contained 195,806 SNPs that were genotyped on TEDDY
study DNA samples. Principal components analysis (PCA)
using EIGENSTRAT software (Department of Genetics,
Harvard Medical School, Boston, MA, USA) was performed
using each unrelated TEDDY study participant to estimate
ancestry, with the two most significant principal components
used as covariates in analytical models. For our primary
hypothesis on SNPs in ascorbic acid pathways, SLC23A1
(rs33972313), SLC2A1 (rs1105297 and rs3754223) and
SLC2A2 (rs5400) were on the ImmunoChip, passed quality
control metrics and were selected for analysis.
Statistical analyses A linear mixed effects model adjusted for
the case–control status was used to examine whether plasma
ascorbic acid over time was different by the use of standard vs
long-distance protocol, country, SNPs and other risk factors
for type 1 diabetes. The random effects for participant were
nested within the random effects for case–control set in the
model. Weight z score and height z score were derived from
Centers for Disease Control and Prevention standardised
growth charts.
Plasma ascorbic acid was analysed up to the case’s event age
specific to each nested case–control set. The measures were
from all visits prior to and including the first of two consecutive
visits at which the child tested positive for an autoantibody for
islet autoimmunity analysis and prior to the diagnosis for type 1
diabetes analysis. The mean of the corresponding measures for
each participant (childhood ascorbic acid) was compared
between matched case and control children. Conditional logis-
tic regression was used to assess the association between the
characteristics of interest and the case–control status.
Interaction term with the matching factors was tested for the
effect modification. All analyses were adjusted for HLA geno-
type (HLA-DR3/4 vs other) and two principal components of
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ancestry to control for population stratification. The log-
linearity of the characteristic with each outcome was examined
using the supremum test [25]. All analyses were performed
using SAS 9.4 (SAS Institute, Cary, NC, USA). A two-sided
p value <0.05 was considered statistically significant.
Results
Background characteristics The mean and SD of childhood
plasma ascorbic acid concentrations are shown according to
matching variables in islet autoimmunity and type 1 diabetes
case–control children in Table 1. The mean (± SD) plasma
ascorbic acid concentration for islet autoimmunity cases and
controls was 10.21 ± 3.33 mg/l and 10.76 ± 3.54 mg/l, respec-
tively. For the type 1 diabetes cases and controls, the mean
(± SD) plasma ascorbic acid concentration was 9.73 ±
3.18 mg/l and 10.58 ± 3.57 mg/l, respectively.
Plasma ascorbic acid concentrations did not differ by the
use of standard protocol vs long-distance protocol. As poten-
tial risk factors for type 1 diabetes, we examined growth vari-
ables (mean height and weight z score prior to the outcome),
as well as breastfeeding status at 3 and 6 months.
Breastfeeding was associated with lower plasma ascorbic acid
status (mixed model regression variables estimate [SE]: −0.96
[0.26], p < 0.001 for breastfeeding vs not breastfeeding at
3 months and −0.77 [0.23], p < 0.001 for breastfeeding vs
not breastfeeding at 6 months) but no significant association
was found with the outcomes. Higher weight or height z
scores were associated with lower plasma ascorbic acid
concentration (−0.28 [0.10], p = 0.006 and −0.12 [0.04], p =
0.001, respectively). Because weight was also associated with
islet autoimmunity (OR [95% CI]: 1.23 [1.07, 1.41] for any
islet autoimmunity; 1.24 [1.01, 1.51] for IAA first; 1.32 [1.05,
1.65] for GADA first), we adjusted for mean weight z score in
the models examining ascorbic acid concentration vs
outcomes.
Primary outcomes: islet autoimmunity and type 1 diabetes
Childhood plasma ascorbic acid status was inversely associ-
ated with islet autoimmunity (OR 0.96 [95% CI 0.92, 0.99],
p = 0.04) but the association with type 1 diabetes risk was not
significant (OR 0.93 [95% CI 0.86 1.02], p = 0.11) (Table 2).
Adjustment for mean weight z score prior to the outcome
showed a similar pattern: islet autoimmunity OR 0.96 (95%
CI 0.92, 1.00), p = 0.06; type 1 diabetes OR 0.93 (95% CI
0.86, 1.02), p = 0.11. All the outcome analyses were adjusted
for ethnicity and HLA-DR3/4 genotype. The association
between plasma ascorbic acid concentration and risk of islet
autoimmunity and type 1 diabetes was not modified by the
participant HLA-DR3/4 genotype, clinical centre, sex or fami-
ly history of type 1 diabetes.
Table 1 Mean childhood plasma
ascorbic acid in islet autoimmu-
nity and type 1 diabetes cases and
controls
Matching variable Islet autoimmunity Type 1 diabetes
No. (%) of cases Plasma ascorbic acid
concentration (mg/l)a
No. (%)
of cases
Plasma ascorbic acid
concentration (mg/l)a
Cases Controls Cases Controls
Clinical centre
Colorado 51 (14.6) 11.7 ± 3.0 12.2 ± 3.3 15 (14.7) 12.0 ± 2.5 12.2 ± 3.1
Georgia 24 (6.9) 12.5 ± 3.5 12.3 ± 3.4 6 (5.9) 13.1 ± 4.2 13.6 ± 4.1
Washington State 34 (9.7) 11.4 ± 4.3 11.8 ± 4.4 7 (6.9) 9.8 ± 3.5 11.6 ± 3.2
Finland 105 (30.0) 10.5 ± 2.8 10.7 ± 3.0 35 (34.3) 9.8 ± 2.7 10.7 ± 3.6
Germany 26 (7.4) 9.2 ± 2.5 9.7 ± 3.4 15 (14.7) 10.2 ± 3.2 10.3 ± 3.8
Sweden 110 (31.4) 8.7 ± 3.0 9.5 ± 3.6 24 (23.5) 7.9 ± .9 8.8 ± 3.0
Sex
Female 157 (44.9) 10.0 ± 3.4 10.7 ± 3.5 47 (46.1) 10.2 ± 3.1 10.2 ± 3.1
Male 193 (55.1) 10.4 ± 3.2 10.8 ± 3.7 55 (53.9) 9.7 ± 3.3 11.2 ± 4.0
FDR/GP status
FDR 76 (21.7) 10.8 ± 3.1 11.1 ± 3.7 36 (35.3) 10.8 ± 2.8 11.0 ± 3.8
GP 274 (78.3) 10.0 ± 3.4 10.7 ± 3.5 66 (64.7) 9.5 ± 3.4 10.6 ± 3.6
Plasma ascorbic acid concentrations are presented as mean ± SD
aMean childhood plasma ascorbic acid; includes measures from all visits prior to and including the seroconver-
sion visit, which is the first of two consecutive visits at which the child tested positive for an autoantibody. To
convert ascorbic acid concentration to μmol/l, multiply values in mg/l by 5.678
FDR, first-degree relative of an individual with type 1 diabetes; GP, from the general population (no first-degree
relative with type 1 diabetes)
Diabetologia (2020) 63:278–286282
Secondary outcomes: IAA first and GADA firstChildhood plas-
ma ascorbic acid status was inversely associated with the risk
of IAA first (OR 0.94 [95% CI 0.88, 0.99], p = 0.03).
Adjustment for mean weight z score prior to the outcome
produced similar results (OR 0.93 [95% CI 0.88, 0.99], p =
0.03). Plasma ascorbic acid concentration was not associated
with GADA first (OR 0.99 [95% CI 0.93, 1.07], p = 0.99). All
the outcome analyses were adjusted for ethnicity and HLA-
DR3/4 genotype. The HLA-DR3/4 genotype did not modify
the association between plasma ascorbic acid concentration
and the risk of IAA first or risk of GADA first.
SNPs and outcomes and effect modification by SNPs The
SLC23A1 rs33972313 minor allele carriers had lower mean
plasma ascorbic acid concentration than non-carriers (mixed
model regression variable estimate [SE]: −2.22 [0.46],
p < 0.001). However, the SNPwas not associated with the risk
of islet autoimmunity or type 1 diabetes (Table 3), nor with
IAA first or GADA first (data not shown). Furthermore,
SLC23A1 rs33972313 did not modify the association between
plasma ascorbic acid and the risk of islet autoimmunity or type
1 diabetes (Table 3), IAA first (interaction p = 0.43) or GADA
first (interaction p = 0.10). DHA transport gene SNPs in
SLC2A1 (rs1105297 and rs3754223) were not associated with
plasma ascorbic acid concentration (p = 0.32 and p = 0.76) or
the risk of islet autoimmunity, type 1 diabetes, IAA first or
GADA first, either alone or in conjunction with the plasma
ascorbate status. They did not modify the association between
plasma ascorbic acid and the risk of islet autoimmunity or type
1 diabetes (Table 3), IAA first or GADA first (data not
shown).
SLC2A2 rs5400 was not associated with plasma ascorbic
acid concentration (p = 0.54) or the risk of islet autoimmunity,
IAA first or GADA first; however, SLC2A2 rs5400 was asso-
ciated with increased risk of type 1 diabetes (OR 1.66 [95%CI
1.06, 2.60], p = 0.028) (Table 3). The association remained
even after adjusting for plasma ascorbic acid in addition to
the two largest principal components for ethnicity and HLA-
DR3/4 genotype. In this model, rs5400 was associated with
increased risk of type 1 diabetes (OR 1.77 [95% CI 1.12,
2.80], p = 0.015), while plasma ascorbic acid concentration
showed no association (OR 0.92 [95% CI 0.84, 1.00], p =
0.058). The SLC2A2 rs5400 SNP did not modify the associa-
tion of plasma ascorbic acid status with the risk of islet auto-
immunity or type 1 diabetes, IAA first or GADA first.
Discussion
In this relatively large prospective study, mean ascorbic acid
concentration in plasma was inversely associated with the risk
of islet autoimmunity, but not type 1 diabetes, in children with
increased genetic risk of type 1 diabetes. The association between
ascorbic acid and type 1 diabetes was, however, only marginally
different and showed a stronger point estimate compared with
islet autoimmunity. The SNPs investigated in our study (i.e.
SNPs in ascorbic acid or dehydroascorbic acid transport genes)
did notmodify the observed associationswith islet autoimmunity
and the SNPs themselves were not associated with islet autoim-
munity. However, the presence of the minor alleles in SLC2A2
rs5400 appeared to increase the risk of type 1 diabetes.
Furthermore, SNP rs33972313 in SLC23A1was associated with
lower plasma ascorbic acid concentrations, in line with previous
studies, and appeared to increase type 1 diabetes risk, although
the finding was of borderline significance (p = 0.06).
One of the strengths of our study is the large multinational
study sample with multiple measurements of plasma ascorbic
acid as well as genetic information. To our best knowledge,
our study is the first one to assess prospectively whether plas-
ma ascorbic acid concentration (and genetic variation related
to ascorbic acid) is associated with development of islet auto-
immunity and type 1 diabetes. Measurement of ascorbic acid
concentration in the plasma may more accurately reflect avail-
ability to tissues, as compared with dietary intake measure-
ments. Previous case–control studies have assessed ascorbic
acid intake from diet and supplements using questionnaire [7,
8]. Another strength is that we were able to investigate the
endpoints of IAA first and GADA first separately; this is
important because they may reflect different disease process-
es. IAA usually appears during the first to second year of life,
whereas GADA usually appears at 3–5 years of age or even
later [26, 27]. In other words, we were able to study associa-
tions of plasma ascorbic acid at very early stages of autoim-
munity development. A limitation of our study is the use of
array platform for measuring genetic information on SNPs, as
this might not determine the target genes accurately.
Table 2 Risk of type 1 diabetes-related outcomes associated with child-
hood plasma ascorbic acid
Outcome OR (95% CI)a p value
Islet autoimmunity
(cases, n = 350)
0.96 (0.92, 0.99) 0.041
Type 1 diabetes
(cases, n = 102)
0.93 (0.86, 1.02) 0.109
IAA first
(cases, n = 163)
0.94 (0.88, 0.99) 0.028
GADA first
(cases, n = 120)
0.99 (0.93, 1.07) 0.988
Data are presented as OR (95% CI) per 1 mg/l increase in childhood
ascorbic acid concentration
Mean childhood plasma ascorbic acid includes measures from all visits
prior to and including the seroconversion visit, which is the first of two
consecutive visits at which the child tested positive for an autoantibody,
and for type 1 diabetes all visits prior to diagnosis. To convert ascorbic
acid concentration to μmol/l, multiply values in mg/l by 5.678
aAdjusted for two largest principal components for ethnicity and HLA-
DR3/4 genotype
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Furthermore, besides HLA type and ethnicity, we could not
take into account other potential confounding factors that
might affect ascorbic acid status (e.g. endogenous stress such
as infection or genetic variation of proteins regulating oxida-
tive stress such as glutathione S-transferases and haptoglobin
[9, 10]). Other limitations of our study are that it included only
children who developed type 1 diabetes at a very early age
(mean age of diagnosis 29months) and that the follow-up time
(up to 6 years of age) for type 1 diabetes was relatively short.
Our prospective study shows that higher plasma ascorbic
acid concentration was associated with lower risk of islet auto-
immunity, in particular with lower risk of IAA first. The
results indicate that vitamin Cmight be protective, particularly
during the early stages of autoimmunity development or early
in life. This is in line with previous findings linking other early
dietary exposures to IAA [16, 28].
Our study confirms previous findings that carrying the
SLC23A1 gene SNP rs33972313 minor alleles results in
reduced plasma ascorbic acid concentration [11]. The pres-
ence of the minor ‘A’ allele, results in a change from the valine
(Val/GTG) form to the methionine (Meth/ATG) form [11].
This alters the function the vitamin C transport proteins,
impairing the active transport of ascorbic acid via decreased
renal reabsorption, increased excretion and altered dose–
response of plasma ascorbic acid [29].
Our study included SNPs in genes involved in the transport
of DHA as well as ascorbic acid. Genetic variation in ascorbic
acid transport would appear more important, because vitamin C
mainly enters cells as L-ascorbic acid. However, vitamin C is
also taken up as DHA, which is the oxidised form of ascorbic
acid and is reduced back to ascorbic acid intracellularly. DHA
transport occurs through five glucose transporters encoded by
the SLC2A solute carrier gene family [30–33]. SNPs in any of
these transport-protein-encoding genes could affect cellular
ascorbate status and they are therefore all of interest in our study.
None of the SNPs investigated modified the associations
between plasma ascorbic acid and the outcomes. In addition,
our results do not imply any association between the SNPs
and islet autoimmunity. However, a common variant in the
SLC2A2 gene (rs5400) was associated with an increased risk
of type 1 diabetes, while a less frequent variant in SLC23A1
(rs33972313) showed an association of borderline statistical
significance. More studies are needed to corroborate the find-
ings and to investigate the underlying mechanisms, because
they may be related to other functions of these proteins.
Of the SNPs investigated, only rs33972313 in the
SLC23A1 gene has been shown to reduce ascorbic acid status
[11]. SLC2A proteins are well-known glucose transporters,
with the proteins encoded by SLC2A1 and SLC2A3 being
more essential for pancreatic glucose transport in humans,
compared with proteins encoded by SLC2A2, because they
are expressed at higher levels. A previous study found an
association between SLC2A2 SNP rs5400 and an increased
risk of type 2 diabetes [34] but we are not aware of studies
linking the SNP to type 1 diabetes.
In this study, children who were not breastfed at 3 or
6 months of age had higher plasma ascorbic acid concentra-
tion compared with children who were breastfed for longer.
This may result from early introduction of complementary
foods containing higher amounts of vitamin C. Although a
child’s plasma ascorbic acid status might be affected bymater-
nal intake of vitamin C, there are no studies assessing the
association between maternal intake of vitamin C during lacta-
tion and a child’s risk of islet autoimmunity and type 1 diabe-
tes. The mother’s adequate vitamin C status during pregnancy
is important to the development of the fetus [35] and may
affect the child’s risk of developing type 1 diabetes. However,
in a previous study, maternal vitamin C intake during pregnan-
cy was found not to be associated with the child’s risk of islet
autoimmunity or type 1 diabetes in a population with adequate
vitamin C intake [36]. It should be noted that the associations
Table 3 Risk of islet autoimmunity and type 1 diabetes associated with ascorbic acid transport gene polymorphisms and effect modification between
the genes and childhood plasma ascorbic acid on the islet autoimmunity and type 1 diabetes risk
Gene SNP (minor allele) Islet autoimmunity Type 1 diabetes
% of minor allele,
cases/controls
OR (95% CI)a p valuea p valueb % of minor
allele, cases
/controls
OR (95% CI)a p valuea p valueb
SLC23A1c rs33972313 (A) 3.4/2.8 1.18 (0.70, 1.99) 0.533 0.158 5.4/1.6 2.52 (0.96, 6.59) 0.060 0.101
SLC2A1c rs1105297 (A) 33.7/32.8 1.04 (0.86, 1.26) 0.690 0.094 33.8/32.6 1.09 (0.75, 1.56) 0.661 0.175
SLC2A1c rs3754223 (A) 21.9/22.7 0.92 (0.74, 1.15) 0.473 0.959 25.5/21.6 1.40 (0.93, 2.11) 0.107 0.665
SLC2A2c rs5400 (A) 12.7/13.7 0.90 (0.69, 1.16) 0.408 0.456 18.6/11.7 1.66 (1.06, 2.60) 0.028 0.785
aAdjusted for two largest principal components for ethnicity and HLA-DR3/4 genotype
b Indication of interaction of childhood plasma ascorbic acid with the number of transport gene SNP alleles on the risk of islet autoimmunity and type 1
diabetes, adjusted for two largest principal components for ethnicity and HLA-DR3/4 genotype
c Genetic data were missing from two islet autoimmunity cases, one type 1 diabetes case and five controls
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between ascorbic acid and type 1 diabetes outcomes may be
different at different intake levels or plasma concentrations and
inter-individual differences could also play a role. Different
results may be observed in studies performed in vitamin C-
deficient populations or in supplementation trials.
It has been suggested that higher weight gain during infan-
cy and/or childhood is related to increased risk of islet auto-
immunity and type 1 diabetes [37, 38]. In the current study,
mean weight prior to islet autoimmunity was associated with
islet autoimmunity outcomes but adjustment for weight did
not change the association between plasma ascorbic acid
concentration and the outcomes.
The associations observed in this study are novel and rela-
tively weak. Further studies are therefore needed to corrobo-
rate the findings.
Conclusions Higher plasma ascorbic acid may reduce the risk
of islet autoimmunity in childrenwith increased genetic risk of
type 1 diabetes. Furthermore, genetic variation in vitamin C
and glucose transporters might play a role in the development
of type 1 diabetes. Further studies are warranted to elucidate
the role of vitamin C in type 1 diabetes development.
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